An Interventional Study of Infigratinib in Children With Hypochondroplasia
Public ClinicalTrials.gov record NCT06873035. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2/3, Multicenter, Open-Label Phase Followed by a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Infigratinib in Children With Hypochondroplasia: ACCEL 2/3
Study identification
- NCT ID
- NCT06873035
- Recruitment status
- Enrolling by invitation
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Enrollment
- 24 participants
Conditions and interventions
Conditions
Interventions
- infigratinib 0.128 mg/kg/day Drug
- infigratinib 0.25 mg/kg/day Drug
Drug
Eligibility (public fields only)
- Age range
- 3 Years to 18 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 21, 2025
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
- Last update posted
- Dec 14, 2025
2025 – 2027
United States locations
- U.S. sites
- 7
- U.S. states
- 7
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCSF Benioff Children's Hospital | Oakland | California | 94609 | — |
| Childrens Hospital Colorado | Aurora | Colorado | 80045 | — |
| Children's National Hospital | Washington D.C. | District of Columbia | 20010 | — |
| Johns Hopkins School of Medicine | Baltimore | Maryland | 21287 | — |
| University of Missouri | Columbia | Missouri | 65201 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| University of Wisconsin Madison - Waisman Center Bone Dysplasia Clinic | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06873035, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 14, 2025 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06873035 live on ClinicalTrials.gov.